Starton Therapeutics Reports Positive Results From Phase 1 Study Evaluating Star-Lld Continuous Delivery Lenalidomide
Star-Lld Well Tolerated With No Dose-Related Toxicity Or Adverse EventsStar Lld Achieved 90% Bioavailability Across All DosesPlasma Levels Showed A 90% Lower Cmax, A 70% Lower Auc, And Sustained Cmin At Targeted Dose LevelsStudy Validated Compatibility And Utility Of Ambulatory Pump Delivery System With Star-Lld Subcutaneous FormulationStarton Therapeutics Inc., A Clinical Stage Biotechnology Company Announced Today Positive Results From High-Level Data From Its Phase 1 Study Of Star-Lld, Evaluating The Pharmacokinetics (Pk) And Safety Of The Company
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!